Michel, managing partner, joined Thuja Capital early 2008. Prior to that he held senior management positions both in the international pharmaceutical industry (e.g. Janssen Pharmaceutica (Belgium), Yamanouchi (currently Astellas Pharma)) as well as in the biotech industry (Crucell). Michel holds an MSc degree in Pharmacy (Utrecht University) and a PhD in Pharmacology (Wageningen University), as well as a post-doctoral degree in Pharmaceutical Medicine (Dip.Phar.Med., European Center for Pharmaceutical Sciences, Basle).

Tyler, principal, joined Thuja in early 2023. He worked previously as a consultant at Boston Consulting Group and intern at Novartis Venture Fund. Tyler completed his medical training at Harvard, where he also conducted research on improving blood stem cell engraftment after transplantation. Prior to Harvard, Tyler led a research project at King’s College London which elucidated the role of common genetic mutations in oral cancer. He was a 2012 Fulbright Scholar to EPFL, Switzerland. Tyler holds an MD from Harvard Medical School, an MRes in Translational Cancer Medicine from King’s College London, an MBA from London Business School, and a BSc in Cell & Molecular Biology from Duke University.

Eleanor, Analyst, joined Thuja in early 2022. Prior to that she was a Consultant at IQVIA, where she focused on commercial strategy for pharmaceutical products and commercial due diligence to support private equity investments in healthcare. She previously led the operations of a biotech accelerator, PanaceaStars, based in Oxford UK. Eleanor holds a BSc in Cellular and Molecular Medicine (University of Bristol), a PhD in Cardiovascular Regenerative Medicine (University of Oxford) and she completed an online MBA at the Quantic School of Business and Technology.